In the era of personalized medicine, cancer patients will often have their tumors biopsied and analyzed as doctors hunt for mutations that are driving the patient’s condition. For some forms of cancer, doctors can recommend therapies that target particular genetic changes.
“The problem is – and this is why cancer is such a tough disease to treat – cancer transforms and changes. So a patient may be diagnosed with a particular mutation and a year later they may have different mutations. Unless we go in and biopsy the patient again and again and again, which can’t be done because it’s just too risky, the only information you have is the information on day one,” Ilan Danieli told Drug Delivery Business News.
But liquid biopsies, like the ones made by Danieli’s company Precipio (NSDQ:PRPO), could change that.
Get the full story at our sister site, Drug Delivery Business News.
The post Tracking tumors with Precipio’s liquid biopsy tech appeared first on MassDevice.